OSELTAMIVIR PHOSPHATE capsule

Země: Spojené státy

Jazyk: angličtina

Zdroj: NLM (National Library of Medicine)

Aktivní složka:

OSELTAMIVIR PHOSPHATE (UNII: 4A3O49NGEZ) (OSELTAMIVIR CARBOXYLATE - UNII:K6106LV5Q8)

Dostupné s:

A-S Medication Solutions

Podání:

ORAL

Druh předpisu:

PRESCRIPTION DRUG

Terapeutické indikace:

Oseltamivir Phosphate capsule USP is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Oseltamivir Phosphate capsule USP is indicated for the prophylaxis of influenza A and B in patients 1 year and older. - Oseltamivir Phosphate capsule USP is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. - Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir Phosphate Capsule USP [see Microbiology (12.4)]. - Oseltamivir Phosphate capsule USP is

Přehled produktů:

Product: 50090-4783 NDC: 50090-4783-0 10 CAPSULE in a BLISTER PACK

Stav Autorizace:

Abbreviated New Drug Application

Charakteristika produktu

OSELTAMIVIR PHOSPHATE- OSELTAMIVIR PHOSPHATE CAPSULE
A-S MEDICATION SOLUTIONS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
OSELTAMIVIR PHOSPHATE CAPSULE
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
OSELTAMIVIR PHOSPHATE CAPSULE.
OSELTAMIVIR PHOSPHATE CAPSULE, FOR ORAL USE
INITIAL U.S. APPROVAL: 1999
INDICATIONS AND USAGE
Oseltamivir Phosphate capsule USP is an influenza neuraminidase
inhibitor (NAI) indicated for:
Treatment of acute, uncomplicated influenza A and B in patients 2
weeks of age and older who have been symptomatic
for no more than 48 hours. (1.1)
Prophylaxis of influenza A and B in patients 1 year and older. (1.2)
Limitations of Use:
Not a substitute for annual influenza vaccination. (1.3)
Consider available information on influenza drug susceptibility
patterns and treatment effects when deciding whether to
use. (1.3)
Not recommended for patients with end-stage renal disease not
undergoing dialysis. (1.3)
DOSAGE AND ADMINISTRATION
Treatment of influenza
Adults and adolescents (13 years and older): 75 mg twice daily for 5
days (2.2)
Paediatric patients 1 to 12 years of age: Based on weight twice daily
for 5 days (2.2)
Paediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice
daily for 5 days (2.2)
Renally impaired adult patients (creatinine clearance >30-60 mL/min):
Reduce to 30 mg twice daily for 5 days (2.4)
Renally impaired adult patients (creatinine clearance >10-30 mL/min):
Reduce to 30 mg once daily for 5 days (2.4)
ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30
mg after every hemodialysis cycle.
Treatment duration not to exceed 5 days (2.4)
ESRD patients on CAPD: Reduce to a single 30 mg dose immediately (2.4)
Prophylaxis of influenza
Adults and adolescents (13 years and older): 75 mg once daily for at
least 10 days (2.3)
Community outbreak: 75 mg once daily for up to 6 weeks (2.3)
Pediatric patients 1 to 12 years of age: Based on weight once daily
for 10 days (2.3)
Community